Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 3/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 3/20 | 0.49 |
| ▸ | GHSR | Q92847 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426088 | 1.00 | FCER2 (0.53) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL6317992 | 1.00 | FCER2 (0.53) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL6318813 | 0.93 | MMP9 (0.47) | FCER2MMP9MMP8F2MMP2 | |
| SCHEMBL8711092 | 0.93 | MMP9 (0.47) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL8905784 | 0.92 | MMP1 (0.48) | FCER2MMP9MMP8F2MMP2 | |
| SCHEMBL3266812 | 0.91 | MMP9 (0.47) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL6324655 | 0.90 | MME (0.47) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL8715806 | 0.90 | FCER2 (0.52) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL6320694 | 0.90 | MMP9 (0.56) | FCER2MMP9MMP8GHSRMME | |
| SCHEMBL6848992 | 0.89 | MMP9 (0.46) | FCER2MMP9MMP8GHSRMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869974-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2009-03-04 | — | — | EP | claimed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | claimed |
| EP-0869974-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2009-03-04 | — | — | EP | disclosed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6849597-B2 | Neuroprotective drug | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| US-6784158-B1 | SECRETAGOGUE WHICH CAN BE USED IN TREATING MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2004-08-31 | — | — | US | disclosed |
| US-20040063641-A1 | Use of growth hormone or a growth hormone secretagogue for promoting bone formation | RASCHKE MICHAEL (DE) | 2004-04-01 | — | — | US | disclosed |
| EP-1060190-B1 | NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE | NOVO NORDISK AS (DK) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| WO-1999064456-A1 | A METHOD FOR PREPARING A COMPOUND WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-12-16 | — | — | WO | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0941115-A1 | USE OF GROWTH HORMONE OR A GROWTH HORMONE SECRETAGOGUE FOR PROMOTING BONE FORMATION | NOVO NORDISK A/S (DK) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999045029-A1 | NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE | NOVO NORDISK A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
| EP-0907374-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1999-04-14 | — | — | EP | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998019699-A1 | USE OF GROWTH HORMONE OR A GROWTH HORMONE SECRETAGOGUE FOR PROMOTING BONE FORMATION | NOVO NORDISK A/S (DK) | 1998-05-14 | — | — | WO | disclosed |
| WO-1997046252-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063641-A1 | Use of growth hormone or a growth hormone secretagogue for promoting bone formation | GHSR, GHRHR, BMP2 | FCER2 3139/4885MMP9 1230/4885MMP8 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.